Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Enliven Therapeutics, Inc.

NASDAQ: ELVN · Life Sciences · 8 alerts · CIK 1672619

Share price
$47.62Close, Nov 16
Market cap
$3.5B
Shares outstanding
73.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Enliven Therapeutics, Inc. filings on SEC EDGAR ↗

4:40 PM ET 8-K
Leadership Change

Enliven Therapeutics Leadership Change

Enliven Therapeutics appointed Kristine Ball to its Board of Directors and Audit Committee, effective October 14, 2026. Ms. Ball, an experienced biopharmaceutical executive, joins as the company prepares to initiate a pivotal Phase 3 trial for relcobatinib. Her compensation includes $55,000 in annual cash fees and stock options valued at approximately $650,000.

Counterparty
Kristine Ball

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.